The trading price of Halozyme Therapeutics Inc (NASDAQ:HALO) closed lower on Tuesday, May 27, and closing at $54.42, -0.22% lower than its previous close.
The company’s P/E ratio in the trailing 12-month period was 14.44. In examining the 52-week price action we see that the stock hit a 52-week high of $70.50 and a 52-week low of $42.01. Over the past month, the stock has lost -10.03% in value.
Halozyme Therapeutics Inc, whose market valuation is $6.71 billion at the time of this writing, is expected to release its quarterly earnings report in June. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 1.2 per share this quarter, however they have predicted annual earnings per share of 5.32 for current year and 6.59 for next year.
Analysts have forecast the company to bring in revenue of 282.66M for the current quarter, with the likely lows of 278M and highs of 288M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 1.24B.
On the technical side, indicators suggest HALO has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned HALO a recommendation rating is 7. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Halozyme Therapeutics Inc (HALO) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0.50, which symbolizes a positive outlook. A quick review shows that HALO’s price is currently -5.87% off the SMA20 and -9.21% off the SMA50. The RSI metric on the 14-day chart is currently showing 44.28, and weekly volatility stands at 0.87%. When measured over the past 30 days, the indicator reaches 7.86%. Halozyme Therapeutics Inc (NASDAQ:HALO)’s beta value is currently sitting at 1.21, while the Average True Range indicator is currently displaying 3.02. With analysts defining $62-$62 as the low and high price targets, we arrive at a consensus price target of $62 for the trailing 12-month period. The current price is about -13.93% off the estimated low and -13.93% off the forecast high, based on this estimate. Investors will be thrilled if HALO’s share price rises to $62, which is the median consensus price. At that level, HALO’s share price would be -13.93% below current price.
To see how Halozyme Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: HALO stock’s performance was -0.22% in the latest trading, and 19.66% in the past year. Halozyme Therapeutics Inc has a P/E ratio of 14.44.
An evaluation of the daily trading volume of Halozyme Therapeutics Inc (NASDAQ:HALO) indicates that the 3-month average is 2.11 million.
Currently, records show that 123.17 million of the company’s shares remain outstanding. The insiders hold 1.10% of outstanding shares, whereas institutions hold 100.35%. However, since the stock’s price has seen 13.83% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
